Pharmacological intervention strategies for affecting telomerase activity: Future prospects to treat cancer and degenerative disease

Biochimie

Volumn 90, Issue 1, 2008, Pages 156-172

  Tarkanyi I ^a   Aradi, J ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

cancer therapy; telomerase; telomerase activator; telomerase inhibitor

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; 2 (3 NAPHTALEN 2 YLBUT 2 ENOYLAMINO)BENZOIC ACID; 2 [3 (TRIFLUOROMETHYLPHENYL]ISOTHIAZOLIN 3 ONE; 3' AZIDO 2',3' DIDEOXY 2 AMINOPURIN; ACICLOVIR; BENZOIC ACID DERIVATIVE; BETA RUBRAMYCIN; BIBR 1532; CARBOCYCLIC OXETANOCIN DERIVATIVE; CARBOVIR; DEOXYGUANOSINE DERIVATIVE; DIDEOXYGUANOSINE; EPIGALLOCATECHIN GALLATE; FJ 5002; GAMMA RUBROMYCIN; GANCICLOVIR; GERON; GRN 163; HELENALIN; HOLOENZYME; PENCICLOVIR; PEPTIDE NUCLEIC ACID; PHOSPHODIESTERASE; PHOSPHOROTHIOIC ACID; PURPUROMYCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TA 65; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERE BINDING PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

CANCER; CANCER CELL; CANCER THERAPY; CATALYSIS; CELL CYCLE; CELL DEATH; CELL DIVISION; CELL IMMORTALIZATION; CELL PROLIFERATION; CHROMOSOME; CHROMOSOME SIZE; DEGENERATIVE DISEASE; DNA REPLICATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME RECONSTITUTION; ENZYME STRUCTURE; GENE LOSS; GENETIC ANALYSIS; HUMAN; IN VITRO STUDY; MOLECULE; NONHUMAN; PHARMACOLOGY; PROTEIN EXPRESSION; REVIEW; SENESCENCE; STRUCTURE ACTIVITY RELATION; T CELL LEUKEMIA; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL DIVISION; ENZYME INHIBITORS; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE; TELOMERE-BINDING PROTEINS;

EUKARYOTA;

EID: 36749079827     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2007.09.002     Document Type: Review

References (165)

1. Greider C.W., and Blackburn E.H. Identification of a specific terminal transferase activity in Tetrahymena extracts. Cell 43 (1985) 405-413
2. Morin G.B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 49 (1989) 521-529
3. Blackburn E.H. Structure and function of telomeres. Nature 350 (1991) 569-573
4. Moyzis R.K., Buckingham J.M., Cram L.S., Dani M., Deaven L.L., Jones M.D., Meyne J., Ratliff R.L., and Wu J.-R.A. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6622-6626
5. Harley C.B., Futcher A.B., and Greider C.W. Telomeres shorter during aging of human fibroblast. Nature 345 (1990) 458-460
6. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.C., Coviello G.M., Wriht W.E., Weinrich S.L., and Shay W.S. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
7. Holt S.E., and Shay J.W. Role of telomerase in cellular proliferation and cancer. J. Cell Physiol. 180 (1999) 10-18
8. Blackburn E.H. Telomerase and cancer. Mol. Cancer Res. 3 (2005) 477-482
9. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
10. Bryan T.M., and Reddel R.R. Telomere dynamics and telomerase activity in in vitro immortalized human cells. Eur. J. Cancer 33 (1997) 767-773
11. Muntoni A., and Reddel R.R. The first molecular details of ALT in human tumor cells. Hum. Mol. Genet. 14 (2005) R191-R196
12. Tsai H.-J., Huang W.-H., Li T.-K., Tsai Y.-L., Wu K.-J., Tseng S.-F., and Teng S.-C. Involvement of topoisomerase III in telomere-telomere recombination. J. Biol. Chem. 281 (2006) 13717-13723
13. Lingner J., Hughes T.R., Shevchenko A., Mann M., Lundlab V., and Cech T.R. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276 (1997) 561-567
14. Banik S.S., Guo C., Smith A.C., Margolis S.S., Richardson D.A., Tirado C.A., and Counter C.M. C-terminal regions of the human telomerase catalytic subunit essential for in vivo enzyme activity. Mol. Cell. Biol. 22 (2002) 6234-6246
15. Kelleher C., Teixeira M.T., Forstemann K., and Lingner J. Telomerase: biochemical considerations for enzyme and substrate. Trends Biochem. Sci. 27 (2002) 572-579
16. Huard S., and Autexier C. Human telomerase catalyzes nucleolytic primer cleavage. Nucleic Acids Res. 32 (2004) 2171-2180
17. Chen J.L., Blasco M.A., and Greider C.W. Secondary structure of vertebrate telomerase RNA. Cell 100 (2000) 503-514
18. Mitchell J.R., Wood E., and Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402 (1999) 551-555
19. Cohen S.B., Graham M.E., Lovrecz G.O., Bache N., Robinson P.J., and Reddel R.R. Protein composition of catalytically active human telomerase from immortal cells. Science 315 (2007) 1850-1853
20. Wenz C., Enenkel B., Amacker M., Kelleher C., Damm K., and Lingner J. Human telomerase contains two cooperating telomerase RNA molecules. EMBO J. 20 (2001) 3526-3534
21. Beattie T.L., Zhou W., Robinson M.O., and Harrington L. Functional multimerization of the human telomerase reverse transcriptase. Mol. Cell. Biol. 21 (2001) 6151-6160
22. Smith S., and de Lange T. Tankyrase promotes telomere elongation in human cells. Curr. Biol. 10 (2000) 1299-1302
23. Karlseder J., Broccoli D., Dai Y., Hardy S., and de Lange S.T. p53 and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283 (1999) 1321-1325
24. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat. Rev. Genet. 6 (2005) 611-622
25. Mergny J.L., Lacroix L., Teulade-Fichou M.F., Hounsou C., Guittat L., Hoarau M., Arimondo P.B., Vigneron J.P., Lehn J.M., Riou J.F., Garestier T., and Helene C. Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 3062-3067
26. Shammas M.A., Shmookler Reis R.J., Li C., Koley H., Hurley L.H., Anderson K.C., and Munshi N.C. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin. Cancer Res. 10 (2004) 770-776
27. Gomez D., Wenner T., Brassart B., Douarre C., O'Donohue M.F., El Khoury V., Shin-ya K., Morjani H., Trentesaux C., and Riou J.F. Telomestatin induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells. J. Biol. Chem. 281 (2006) 38721-38729
28. Olaussen K.A., Dubrana K., Domont J., Spano J.P., Sabatier L., and Soria J.C. Telomeres and telomerase as targets for anticancer drug development. Clin. Rev. Oncol. Hematol. 57 (2006) 191-214
29. Pendino F., Tarkanyi I., Dudognon C., Hillion J., Lanotte M., Aradi J., and Ségal-Bendirdjian E. Telomeres and telomerase: pharmacological targets for new anticancer strategies?. Curr. Cancer Drug Targets 6 (2006) 147-180
30. Shay J.W., and Wright W.E. Telomerase therapeutics for cancer: challenges and new directions. Nat. Rev. Drug Discov. 5 (2006) 577-584
31. Artandi S.E. Telomeres, telomerase, and human disease. N. Engl. J. Med. 355 (2006) 1195-1197
32. Zimmermann S., and Martens U.M. Telomeres and telomerase as targets for cancer therapy. Cell. Mol. Life Sci. 64 (2007) 906-921
33. Kim N.W., and Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 25 (1997) 2595-2597
34. Wright W.E., Shay J.W., and Piatyszek M.A. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res. 23 (1995) 3794-3795
35. Szatmari I., To{combining double acute accent}kés S., Dunn C.B., Bardos T.J., and Aradi J. Modified telomeric repeat amplification protocol: a quantitative radioactive assay for telomerase without using electrophoresis. Anal. Biochem. 282 (2000) 80-88
36. Szatmari I., and Aradi J. Telomeric repeat amplification, without shortening or lengthening of the telomerase products: a method to analyze the processivity of telomerase enzyme. Nucleic Acids Res. 29 (2001) E3
37. Herbert B.-S., Hochreiter A.E., Wright W.E., and Shay J.W. Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol. Nat. Protocols 1 (2006) 1583-1590
38. Piotrowska K., Kleideiter E., Mürdter T.E., Taetz S., Baldes C., Schaefer U., Lehr C.M., and Klotz U. Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors. Lab. Invest. 85 (2005) 1565-1569
39. Saldanha S.N., Andrews L.G., and Tollefsbol T.O. Analysis of telomerase activity and detection of its catalytic subunit, hTERT. Anal. Biochem. 315 (2003) 1-21
40. Wege H., Chui M.S., Le H.T., Tran J.M., and Zern M.A. SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity. Nucleic Acids Res. 31 (2003) E3
41. Huang Y.-P., Liu Z.-S., Tang H., Liu M., and Li X. Real-time telomeric repeat amplification protocol using the duplex scorpion and two reverse primers system: the high sensitive and accurate method for quantification of telomerase activity. Clin. Chim. Acta. 372 (2006) 112-119
42. Damm K., Hemmann U., Garin-Chesa P., Hauel N., Kauffmann I., Priepke H., Niestroj C., Daiber C., Enenkel B., Guilliard B., Lauritsch I., Müller E., Pascolo E., Sauter G., Pantic M., Martens U.M., Wenz C., Lingner J., Kraut N., Rettig W.J., and Schnapp A. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 20 (2001) 6958-6968
43. Hahn W.C., Stewart S.A., Brooks M.W., York S.G., Eaton E., Kurachi A., Beijersbergen R.L., Knoll J.H.M., Meyerson M., and Weinberg R.A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5 (1999) 1164-1170
44. Teng L., Specht M.C., Barden C.B., and Fahey T.J. Antisense hTERT inhibits thyroid cancer cell growth. J. Clin. Endocrinol. Metab. 88 (2003) 1362-1366
45. Folini M., Berg K., Millo E., Villa R., Prasmickaite L., Daidone M.G., Benatti U., and Zaffaroni N. Photochemical internalization of a peptide nucleic acid targeting the catalytic subunit of human telomerase. Cancer Res. 63 (2003) 3490-3494
46. Li S., Rosenberg J.E., Donjacour A.A., Botchkina I.L., Hom Y.K., Cunha G.R., and Blackburn E.H. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res. 64 (2004) 4833-4840
47. Li S., Crothers J., Haqq C.M., and Blackburn E.H. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J. Biol. Chem. 280 (2005) 23709-23717
48. Lai S.R., Cunningham A.P., Huynh V.Q., Andrews L.G., and Tollefsbol T.O. Evidence of extra-telomeric effects of hTERT and its regulation involving a feedback loop. Exp. Cell Res. 313 (2007) 322-330
49. Brambilla C., Folini M., Gandellini P., Daprai L., Daidone M.G., and Zaffaroni N. Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells. Cell. Mol. Life Sci. 61 (2004) 1764-1774
50. Saretzki G., Ludwig A., von Zglinicki T., and Runnebaum I.B. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther. 8 (2001) 827-834
51. Stewart S.A., Hahn W.C., O'Connor B.F., Banner E.N., Lundberg A.S., Modha P., Mizuno H., Brooks M.W., Fleming M., Zimonjic D.B., Popescu N.C., and Weinberg R.A. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 12606-12611
52. Smith L.L., Coller H.A., and Roberts J.M. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat. Cell Biol. 5 (2003) 474-479
53. Smogorzewska A., and de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J. 21 (2003) 4338-4348
54. Karlseder J., Smogorzewska A., and de Lange T. Senescence induced by altered telomere state, not telomere loss. Science 295 (2002) 2446-2449
55. Feldser D.M., and Greider C.W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11 (2007) 461-469
56. Schmitt C.A. Cellular senescence and cancer. Review. Biochem. Biophys. Acta 1775 (2007) 5-20
57. Masutomi K., Yu E.Y., Khurts S., Ben-Porath I., Currier J.L., Metz G.B., Brooks M.W., Kaneko S., Murakami S., DeCaprio J.A., Weinberg R.A., Stewart S.A., and Hahn W.C. Telomerase maintains telomere structure in normal human cells. Cell 114 (2003) 241-253
58. Flores I., Benetti R., and Blasco M.A. Telomerase regulation and stem cell behaviour. Curr. Opin. Cell. Biol. 18 (2006) 254-260
59. Mitchell J.R., Cheng J., and Collins K. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3′ end. Mol. Cell. Biol. 19 (1999) 567-576
60. Armanios M., Chen J.L., Chang Y.P., Brodsky R.A., Hawkins A., Griffin C.A., Eshleman J.R., Cohen A.R., Chakravarti A., Hamosh A., and Greider C.W. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenital. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 15960-15964
61. Tsakiri K.D., Cronkhite J.T., Kuan P.J., Xing C., Raghu G., Weissler J.C., Rosenblatt R.L., Shay J.W., and Garcia C.K. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 7552-7557
62. Crabbe L., Jauch A., Neager C.M., Holtgreve-Grez H., and Karlseder J. Telomere dysfunction as a a cause of genomic instability in Werner syndrome. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 2205-2210
63. + T cells in patients with X-linked lymphoproliferative syndrome. Mech. Ageing Dev. 126 (2005) 855-865
64. Dagarag M.D., Ng H., Lubong R., Effros R.B., and Yang O.O. Differential impairment of lytic and cytokine functions in senescent HIV-1-specific cytotoxic T-lymphocytes. J. Virol. 77 (2003) 3077-3083
65. + T cells in SAP-deficient mice is associated with impaired activation-induced cell death. Eur. J. Immunol. 37 (2007) 663-674
66. Monamino T., and Komuro I. Vascular cell senescence. Contribution to atherosclerosis. Circ. Res. 100 (2007) 15-26
67. Fuster J.J., and Andres V. Telomere biology and cardiovascular disease. Circ. Res. 99 (2007) 1167-1180
68. Minamino T., Miyauchi H., Yoshida T., Ishida Y., and Komuro I. Endothelial cell senescence in human atherosclerosis, Role of telomere in endotheial dysfunction. Circulation 105 (2002) 1541-1544
69. Ogami M., Ikura Y., Oshawa M., Matsuto T., Kayo S., Yoshimi N., Hai E., Shira N., Ehara S., Komatsu R., Naruko T., and Ueda M. Telomere shortening in human coronary artery diseases. Atheroscler. Thromb. Vasc. Biol. 24 (2004) 546-550
70. Strahl C., and Blackburn E.H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16 (1996) 53-65
71. Yegorov Y.E., Chernov D.N., Akimov S.S., Bolsheva N.L., Krayevsky A.A., and Zelenin A.V. Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblast. FEBS Lett. 389 (1996) 115-118
72. Flecher T.M., Salazar M., and Chen S.F. Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates. Biochemistry 35 (1996) 15611-15617
73. Gomez D.E., Tejera A.M., and Olivero O.A. Irreversible telomere shortening by 3′-azido-2′, 3′-dideoxythymidine (AZT) treatment. Biochem. Biophys. Res. Commun. 246 (1998) 107-110
74. Tendian S.W., and Parker W.B. Interaction of deoxyguanosine nucleotide analogs with human telomerase. Mol. Pharmacol. 57 (2000) 695-699
75. Yamaguchi T., Takahashi H., Harada Y., Yoshikawa M., Iyono S., Inomata M., Maruyama T., and Saneyoshi M. Telomere shortening in human HL60 cells by treatment with deoxyguanosine analogs. Nucleic Acids Symp. Ser. 48 (2000) 187-188
76. Falchetti A., Franshi A., Bordi C., Mavilia C., Masi L., Cioppi F., Recenti R., Picariello L., Marini F., Del Monte F., Ghinoi V., Martineti V., Tanini A., and Brandi M.L. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J. Bone Miner. Res. 3 (2005) 410-418
77. I.E. Bondarev, Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer (2006) Patent: WO2006US19488 20060518.
78. Ji H.J., Rha S.Y., Jeung H.C., Yang S.H., An S.W., and Chung H.C. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res. Treat. 93 (2005) 227-236
79. Hajek M., Matulova N., Votruba I., Holy A., and Tloustova E. Inhibition of human telomerase by diphosphates of acyclic nucleoside phosphonates. Biochem. Pharmacol. 70 (2005) 894-900
80. Yamaguchi T., Liu X., Ogawara T., Inomata M., and Saneyoshi M. Telomerase inhibition by 3′-azido-2′, 3′-dideoxynuleoside 5′-triphosphates and telomere shortening in human cultured cells by the corresponding nucleosides. Nucleic Acids Symp. Ser. 50 (2006) 271-272
81. Datta A., Bellon M., Sinha-Datta U., Bazarbachi A., Leoelletier Y., Canioni D., Waldmann T.A., Hermine O., and Nicot C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108 (2006) 1021-1029
82. Zhou F.X., Liao Z.K., Dai J., Xiong J., Xie C.H., Luo Z.G., Liu S.Q., and Zhou Y.F. Radiosensitization effect of zidovudine on human malignant glioma cells. Biochem. Biophys. Res. Commun. 354 (2007) 351-356
83. Sluis-Cremer N., Temiz N.A., and Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr. HIV Res. 2 (2004) 323-332
84. Seay T.M., Peretsman S.J., and Dixon P.S. Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinoline antibiotics. J. Urol. 155 (1996) 757-762
85. Yamakuchi M., Nakata M., Kawahara K.-I., Kitajima I., and Maruyama I. New quinolines, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines. Cancer Lett. 119 (1997) 213-219
86. Propper D.J., Braybrooke J.P., Taylor D.J., Lodi R., Styles P., Cramer J.A., Collins W.C., Levitt N.C., Talbot D.C., Ganesan T.S., and Harris A.L. Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. Ann. Oncol. 10 (1999) 923-927
87. Naasani I., Seimiya H., Yamori T., and Tsuruo T. FJ5002: a potent antitelomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 59 (1999) 4004-4011
88. Hayakawa N., Nozawa K., Ogawa A., Kato N., Yoshida K., Akamatsu K.-I., Tsuchiya M., Nagasaka A., and Yoshida S. Isothiazolone derivatives selektively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 38 (1999) 11501-11507
89. Goldman M.E., Salituro G.S., Bowen J.A., Williamson J.M., Zink D.L., Schleif W.A., and Emini E.A. Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: competitive interaction at the template·primer site. Mol. Pharmacol. 38 (1990) 20-25
90. Ueno T., Takahashi H., Oda M., Mizunuma M., Yokoyama A., Goto Y., Mizushina Y., Sakaguchi K., and Hayashi H. Inhibition of human telomerase by rubromycins: implication of spiroketal system of the compounds as an active moiety. Biochemistry 39 (2000) 5995-6002
91. El-Daly H., Kull M., Zimmermann S., Pantic M., Waller C.F., and Martens U.M. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 105 (2005) 1742-1749
92. S. Mueller, U. Hartmann, F. Mayer, S. Balabanov, J.T. Hartmann, T.H. Brummendorf, C. Bokemeyer, Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors. Invest. New Drugs, in press.
93. Ward R.J., and Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol. Pharmacol. 68 (2005) 779-786
94. Pascolo E., Wenz C., Lingners J., Hauel N., Priepke H., Kauffmann I., Garin-Chesa P., Rettig W.J., Damm K., and Schnapp A. Mechanism of human telomerase Inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J. Biol. Chem. 277 (2002) 15566-15572
95. Barma D.K., Elayadi A., Falck J.R., and Corey D.R. Inhibition of telomerase by BIBR1532 and related analogues. Bioorg. Med. Chem. Lett. 13 (2003) 1333-1336
96. Huang P.-R., Yeh Y.-M., and Wang T.V. Potent inhibition of human telomerase by helenalin. Cancer Lett. 227 (2005) 169-174
97. Eitsuka T., Nakagawa K., Suzuki T., and Miyazawa T. Polyunsaturated fatty acids inhibit telomerase activity in DLD-1 human colorectal adenocarcinoma cells: a dual mechanism approach. Biochim. Biophys. Acta 1737 (2005) 1-10
98. Chen Y.-J., Sheng W.-Y., Huang P.-R., and Wang T.-C.V. Potent inhibition of human telomerase by U-73122. J. Biomed. Sci. 13 (2006) 667-674
99. Rangarajan S., and Friedman S.H. Design, synthesis, and evaluation of phenantridine derivatives targeting the telomerase RNA/DNA heteroduplex. Bioorg. Med. Chem. Lett. 17 (2007) 2267-2273
100. Naasani I., Seimiva H., and Tsuruo H.T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem. Biophys. Res. Commun. 249 (1998) 391-396
101. Naasani I., Oh-hashi F., Oh-hara T., Feng W.Y., Johnston J., Chan K., and Tsuruo T. Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res. 63 (2003) 824-830
102. Feng J., Funk W.D., Wang S.-S., Weinrich S.L., Avilion A.A., Chiu C.P., Adams R.R., Chang E., Allsopp R.C., Yu J., Le S., West M.D., Harley C.B., Andrews W.H., Greider C.W., and Villeponteau B. The RNA component of human telomerase. Science 269 (1995) 1236-1241
103. Antal M., Boros E., Solymosy F., and Kiss T. Analysis of the structure of human telomerase RNA in vivo. Nucleic Acids Res. 30 (2002) 912-920
104. Chen J.-L., and Greider C.W. An emerging consensus for telomerase structure. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 14683-14684
105. Wacheck V., and Zangemeister-Wittke U. Antisense molecules for targeted cancer therapy. Crit. Rev. Oncol. Hematol. 59 (2006) 65-73
106. Wilson C., and Keefe A.D. Building oligonucleotide therapeutics using non-natural chemistries. Curr. Opin. Chem. Biol. 10 (2006) 607-614
107. Schiavone N., Donnini M., Nicolin A., and Capaccioli S. Antisense oligonucleotide drug design. Curr. Pharm. Des. 10 (2004) 769-784
108. Gellert G.C., Jackson S.R., Dikmen G., Wright W.E., and Shay J.W. Telomerase as a therapeutic target in cancer. Drug Discov. Today 2 (2005) 159-164
109. Matthes E., and Lehmann Ch. Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res. 27 (1999) 1152-1158
110. 35: a novel, highly potent oligonucleotides inhibitor of the human immunodeficiency virus type-1 reverse transcriptase. FEBS Lett. 396 (1996) 43-46
111. 35. Virology 334 (2005) 214-223
112. Tao M., Miyano-Kurosaki N., Takai K., and Takaku H. Specific inhibition of human telomerase activity by transfection reagent, FuGENE6-antisense phosphorothioate oligonucleotide complex in HeLa cells. FEBS Lett. 454 (1999) 312-316
113. Ye J., Wu Y.L., Zhang S., Chen Z., Guo L.X., Zhou R.Y., and Xie H. Inhibitory effect of human telomerase antisense oligodeoxyribonucleotides on the growth of gastric cancer cell lines in variant tumor pathological subtype. World J. Gastroenterol. 11 (2005) 2230-2237
114. Tao Z., Chen S., Wu Z., Xiao B., Liu J., and Hou W. Targeted therapy of human laryngeal squamous cell carcinoma in vitro by antisense oligonucleotides directed against telomerase reverse transcriptase mRNA. J. Laryngol. Otol. 119 (2005) 92-96
115. Pitts A.E., and Corey D.R. Inhibition of human telomerase by 2′-O-methyl RNA. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11549-11554
116. Herbert B.-S., Pitts A.E., Baker S.I., Hamilton S.E., Wright W.E., Shay J.W., and Corey D.R. Inhibition of human telomerase in immortalhuman cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 14276-14281
117. Folini M., Brambilla C., Villa R., Gandellini P., Vignati S., Paduano F., Daidone M.G., and Zaffaroni N. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur. J. Cancer 41 (2005) 624-634
118. Chen Z., Monia B.P., and Corey D.R. Telomerase inhibition, telomere shortening, and decreased cell proliferation by cell permeable 2′-O-methoxyethyl oligonucleotides. J. Med. Chem. 45 (2002) 5423-5425
119. Elayadi A.N., Demieville A., Wancewicz E.V., Monia B.P., and Corey D.R. Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res. 29 (2001) 1683-1689
120. Chen Z., Koeneman K.S., and Corey D.R. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res. 63 (2003) 5917-5925
121. Nielsen P.E., Egholm M., Berg R.H., and Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254 (1991) 1497-1500
122. Norton J.C., Piatyszek M.A., Wright W.E., Shay J.W., and Corey D.R. Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotech. 14 (1996) 615-619
123. Harrison J.G., Frier C., Laurant R., Dennis R., Raney K.D., and Balasubramanian S. Inhibition of human telomerase by PNA-cationic peptide conjugates. Bioorg. Med. Chem. Lett. 9 (1999) 1273-1278
124. Shammas M.A., Simmons C.G., Corey D.R., and Reis R.J.S. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells. Oncogene 18 (1999) 6191-6200
125. Hamilton S.E., Simmons C.G., Kathiriya I.S., and Corey D.R. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol. 6 (1999) 343-351
126. Clemens M.J., and Williams B.R. Inhibition of cell-free protein synthesis by pppA2′p5′A2′p5′A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell 13 (1978) 565-572
127. Kondo S., Kondo Y., Li G., Silverman R.H., and Cowell J.K. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 16 (1998) 3323-3330
128. Kondo M.S., Kondo Y., Koga S., Komata T., Barna B.P., and Kondo S. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res. 60 (2000) 4461-4467
129. Matthes E., Lehmann Ch., Stulich M., Wu Y., Dimitrova L., Uhlmann E., and von Janta-Lipinski M. Potent inhibitory activity of chimeric oligonucleotides targeting two different sites of human telomerase. Oligonucleotides 15 (2005) 255-268
130. Tarkanyi I., Horváth A., Istvan Szatmari, Eizert H., Vámosi G., Damjanovich S., Ségal-Bendirdjian E., and Aradi J. Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide. FEBS Lett. 579 (2005) 1411-1416
131. Akiyama M., Hideshima T., Shammas M.A., Hayashi T., Hamasaki M., Tai Y.-T., Richardson P., Gryaznov S., Munshi N.C., and Anderson K.C. Effects of oligonucleotide N3′ → P5′ thio-phosphoramidite (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63 (2003) 6187-6194
132. Herbert B.-S., Gellert G.C., Hochreiter A., Pongracz K., Wright W.E., Zielinska D., Chin A.C., Harley C.B., Shay J.W., and Gryaznov S.M. Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidite oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24 (2005) 5262-5268
133. Dikmen Z.G., Gellert G.C., Jackson S., Gryaznov S., Tressler R., Dogan P., Wright W.E., and Shay J.W. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 65 (2005) 7866-7873
134. Hochreiter A.E., Xiao H., Goldblatt E.M., Gryaznov S.M., Miller K.D., Badve S., Sledge G.W., and Herbert B.-S. Telomerase template antagonist GRN163L Disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin. Cancer Res. 12 (2006) 3184-3192
135. Djojosubroto M.W., Chin A.C., Go N., Schaetzlein S., Manns M.P., Gryaznov S., Harley C.B., and Rudolph K.L. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 42 (2005) 1127-1136
136. Falchetti M.L., Fiorenzo P., Mongiardi M.P., Petrucci G., Montano N., Maira G., Pierconti F., Larocca L.M., Levi A., and Pallini R. Telomerase inhibition impairs tumor growth in glioblastoma xenografts. Neurol. Res. 28 (2006) 532-537
137. Shammas M.A., Kolev H., Batchu R.B., Bertheau R.C., protopopov A., Munshi N.C., and Goval R.K. Telomerase inhibition by siRNA causes senescence and apoptosis in Barett's adenocarcinoma cells: mechanism and therapeutic potential. Mol. Cancer 4 (2005) 24
138. Y. Li, H. Li, G. Yao, W. Li, F. Wang, Z. Jiang, M. Li, Inhibition of telomerase RNA (hTR) in cervical cancer by adenovirus-delivered siRNA, Cancer Gene Ther., in press.
139. Marrone A., Sokhal P., Walne A., Beswick R., Kirwan M., Killick S., Williams M., Marsh J., Vulliamy T., and Dokal I. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica 92 (2007) 1013-1020
140. Rowe-Rendleman C., and Glickman R.D. Possible therapy for age-related macular degeneration using human telomerase. Brain Res. Bull. 62 (2004) 549-553
141. Roz N.S., Nakano T., Eyoung H.M., Windrem M., Rashbaum W.K., Alonso M.L., Kang J., Peng W., Carpenter M.K., Lin J., Nedergaard M., and Goldman S.A. Telomerase immortalization of neuronally restricted progenitor cells from human fetal spinal cord. Nat. Biotechnol. 2 (2004) 283-305
142. Mogford J.E., Liu W.R., Reis R., Chiu C., Said H., Chen S., Harley C.B., and Mustoe T.A. Adenoviral human telomerase reverse transcriptase dramatically improves ischaemic wound healing without detrimental immune response in aged rabbit model. Hum. Gene Ther. 17 (2006) 651-660
143. Poh M., Boyer M., Solan A., Dahl S.L.M., Pedrotty D., Banik S.S.R., McKee J.A., Klinger R.Y., Counter C.M., and Niklason L.E. Blood vessels engineered from human cells. Lancet 365 (2005) 2122-2124
144. Allsopp R.C., and Weissman I.L. Replicative senescence of hematiopoietic stem cells during serial transplantation: does telomere shortening play a role?. Oncogene 21 (2002) 3270-3273
145. Ju Y., Jiang H., Jaworski M., Rathinam C., Gompf A., Klein C., Trumpp A., and Rudolph K.L. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat. Med. 13 (2007) 742-747
146. Klinger R.Y., Blum J.L., Hearn B., Lebow B., and Niklason L.E. Relevance and safety of telomerase for human tissue engineering. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 2500-2505
147. Alvero A.B., Fihman D.A., Qumsiyeh M.B., Garg M., Kacinski B.M., and Sapi E. Telomerase prolongs the lifespan of normal human ovarian surface epithelial cells without inducing neoplastic phenotype. J. Soc. Gynecol. Investig. 11 (2004) 553-561
148. Bodnar A.G., Ouelette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., and Wright W.E. Extension of life-span byintroduction of telomerase into normal human cells. Science 279 (1998) 349-352
149. Huang Q., Chen M., Liang S., Acha V., Liu D., Yuan F., Hawks C.L., and Hornsby P.J. Improving cell therapy-experiments using transplanted telomerase-immortalized cells in immunodeficient mice. Mech. Ageing Dev. 128 (2007) 25-30
150. Ugrin M.D., and Harrington L. Strict control of telomerase activation using Cre-mediated inversion. MC Biotechnol. 6 (2006) 10
151. Atkinson S.P., Hoare S.F., Glasspool R.M., and Keith W.N. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res. 65 (2005) 7585-7590
152. Serenicki N., Hoare S.F., Kassem M., Atkinson S.P., and Keith W.N. Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell. Regen. Med. 1 (2006) 125-131
153. Doshida M., Ohmichi M., Tsutsumi S., Kawagoe J., Takahashi T., Du B., Mori-Abe A., Ohte T., Saitoh-Sekiguchi M., Takahashi K., and Hiroshisa K. Raloxifene increases proliferation and up-regulates telomerase activity in human umbilical vein endothelial cells. J. Biol. Chem. 281 (2006) 24270-24278
154. Liu K., Hodes R.J., and Weng N. Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J. Immunol. 166 (2001) 4826-4830
155. Akbar A.N., and Vukmanovic-Stejic M. Telomerase in T lymphocytes: use it and lose it?. J. Immunol. 178 (2007) 6686-6694
156. Passos J.F., Saretzki G., Ahmed S., Nelson G., Richter T., Peters H., Wappler I., Birket M.J., Harold G., Schaeuble K., Birch-Machin M.A., Kirkwood T.B., and von Zglinicki T. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol. 5 (2007) e110
157. Haendeler J., Hoffman J., Diehl J.F., Vasa M., Spyridopoulos I., Zeiher A.M., and Dimmeler S. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. Circ. Res. 94 (2004) 768-775
158. Y. Tanaka, Y. Moritoh, N. Miva, Age-dependent telomere-shortening is repressed by phosphorylated α-tocopherol together with cellular longevity and intracellular oxidative-stress reduction in human brain microvascular endotheliocytes. J. Cell. Biol., in press.
159. Spyridopoulos I., Haendeler J., Urbich C., Brummendorf T.H., Oh H., Schneider M.D., Zeiher A.M., and Dimmeler S. Statins enhance migratory capacity by upregulation of the telomere repeat binding factor TRF2 in endothelial progenitor cells. Circulation 110 (2004) 3136-3142
160. Brouilette S.W., Moore J.S., McMahon A.D., Thompson J.R., Ford I., Shepherd J., Packard C.J., and Samani N.J. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369 (2007) 107-114
161. Dong X.X., Hui Y.J., Xiang W.X., Rong Z.F., Jian S., and Zhu C.J. Ginkgo Biloba extract reduces endothelial progenitor-cell senescence trough augmentation of telomerase activity. J. Cardiovasc. Pharmacol. 49 (2007) 111-115
162. Gandellini P., Folini M., Bandiera R., De Cesare M., Binda M., Veronese S., Daidone M.G., Zunino F., and Zaffaroni N. Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem. Pharmacol. 73 (2007) 1703-1714
163. Beliveau A., Bassett E., Lo A.T., Garbe J., Rubio M.A., Bissell M.J., Campisi J., and Zaswen P. p53-dependent integration of telomere and growth factor deprivation signal. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 4431-4436
164. Montanaro L., Brigotti M., Clohessy J., Barbieri S., Ceccarelli C., Santini D., Taffurelli M., Calienni M., Teruya-Feldstein J., Trere D., Pandolfi P.P., and Derezini M. Dyskerin expression influences the level of ribosomal RNA pseudo-urydilation and telomerase RNA component in human breast cancer. J. Pathol. 210 (2006) 10-18
165. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., Wader T., Tluk S., Liu M., Davis H.L., and Krieg A.M. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34 (2003) 251-262